Scleroderma - Symptoms, Diagnosis, Treatments, Cure & Causes

See useful resources for over 200 ailments at the BillDoll Diseases & Treatments Section, or click on the letter to see all diseases starting with that letter: A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z

Scleroderma-From Wikipedia, the free encyclopedia

This article is about the disease. For the mushroom, see Scleroderma (genus).

Systemic sclerosis

Classification & external resources ICD-10 M34.

ICD-9 710.1

OMIM 181750

DiseasesDB 12845

MedlinePlus 000429

eMedicine med/2076

Scleroderma is a rare, chronic disease characterized by excessive deposits of collagen in the skin or other organs. The localized type of the disease tends not to be fatal. Diffuse scleroderma or systemic sclerosis, the generalized type of the disease, can be fatal as a result of heart, kidney, lung or intestinal damage.

Contents

1 Signs and symptoms

2 Complications

2.1 Musculoskeletal complications

2.2 Pulmonary complications

2.3 Gastrointestinal complications

2.4 Renal complications

3 Diagnosis

4 Types

4.1 Diffuse scleroderma

4.2 Limited scleroderma/CREST syndrome

4.3 Morphea/linear scleroderma

5 Therapy

6 Causes

7 Pathophysiology

8 Epidemiology

9 Patients' advocacy

10 References

11 External links

Signs and symptoms

Scleroderma affects the skin, and in more serious cases it can affect the blood vessels and internal organs. The most evident symptom is the hardening of the skin and associated scarring. Typically, the skin appears reddish or scaly in appearance. Blood vessels may also be more visible. Where large areas are affected, fat and muscle wastage will weaken limbs and affect appearance.

The seriousness of the disease varies hugely between cases. The two most important factors to consider are the level of internal involvement (beneath the skin) and the total area covered by the disease. For example, there have been cases where the patient has no more than one or two lesions, perhaps covering a few inches. Less serious cases tend not to involve the internal bodily functions.

There is discoloration of the hands and feet in response to cold. Most patients (over 80%) have Raynaud's phenomenon, a vascular symptom that can affect the fingers and toes.

Systemic scleroderma and Raynaud's can cause painful ulcers on the fingers or toes which are known as digital ulcers.

Calcinosis is also common in systemic scleroderma, and is often seen near the elbows, knees or other joints.

Complications

Diffuse scleroderma can cause musculoskeletal, pulmonary, gastrointestinal, renal and other complications.[1] Patients with larger amounts of cutaneous involvement are more likely to have involvement of the internal tissues and organs.

Musculoskeletal complications

The first joint symptoms that patients with scleroderma have are typically non specific joint pains, which can lead to arthritis, or cause discomfort in tendons or muscles.[1] Joint mobility, especially of the small joints of the hand, may be restricted by calcinosis or skin thickening.[2] Patients who have progressed later in their disease may develop muscle weakness, or myopathy, either from the disease, or its treatments.[3]

Pulmonary complications

Some impairment in lung function is almost universally seen in patients with diffuse scleroderma on pulmonary function testing;[4] however, it does not necessarily cause symptoms, such as shortness of breath. Some patients can develop pulmonary hypertension, or elevation in the pressures of the pulmonary arteries. This can be progressive, and lead to right sided heart failure. The earliest manifestation of this may be a decreased diffusion capacity on pulmonary function testing.

Other pulmonary complications in more advanced disease include aspiration pneumonia, pulmonary hemorrhage and pneumothorax.[1]

Gastrointestinal complications

Endoscopic image of peptic stricture, or narrowing of the esophagus near the junction with the stomach due to chronic gastroesophageal reflux. This is the most common cause of dysphagia, or difficulty swallowing, in scleroderma.Diffuse scleroderma can affect any part of the gastrointestinal tract.[5] The most common manifestation in the esophagus is reflux esophagitis, which may be complicated by peptic stricturing, or benign narrowing of the esophagus.[6] This is best initially treated with proton pump inhibitors for acid suppression,[7] but may require bougie dilatation in the case of stricture.[5]

Scleroderma can decrease motility anywhere in the gastrointestinal tract.[5] The most common source of decreased motility involvement is the esophagus and the lower esophageal sphincter, leading to dysphagia and chest pain. As Scleroderma progresses, esophageal involvement from abnormalities in decreased motility may worsen due to progressive fibrosis (scarring). If this is left untreated, acid from the stomach can back up into the esophagus causing esophagitis, and GERD. Further scarring from acid damage to the lower esophagus many times leads to the development of fibrotic narrowing, also known as strictures which can be treated by dilitation, and Barrett's esophagus. The small intestine can also become involved, leading to bacterial overgrowth and malabsorption, of bile salts, fats, carbohydrates, proteins, and vitamins. The colon can be involved, and can cause pseudo-obstruction or ischemic colitis.[1]

Rarer complications include pneumatosis cystoides intestinalis, or gas pockets in the bowel wall, wide mouthed diverticula in the colon and esophagus, and liver fibrosis. Patients with severe gastrointestinal involvement can become profoundly malnourished.[6]

Scleroderma may also be associated with gastric antral vascular ectasia (GAVE), also known as watermelon stomach. This is a condition where atypical blood vessels proliferate usually in a radially symmetric pattern around the pylorus of the stomach. GAVE can be a cause of upper gastrointestinal bleeding or iron deficiency anemia in patients with scleroderma.[6]

Renal complications

Renal involvement, in scleroderma, is considered a poor prognostic factor and not infrequently a cause of death in patients with scleroderma.[8]

The most important clinical complication of scleroderma involving the kidney is scleroderma renal crisis.

Symptoms of scleroderma renal crisis are:[9]

Malignant hypertension,

Hyperreninemia,

Azotemia,

Microangiopathic hemolytic anemia and

Renal failure.

Complications of renal crisis include:[10]

Hematuria (blood in the urine),

Hypertension and

Proteinuria.

In the past scleroderma renal crisis was almost uniformily fatal.[11] While outcomes have improved significantly with the use of ACE inhibitors[12][13] the prognosis is often guarded, as a significant number of patients are refractory to treatment and develop renal failure. Approximately 10% of all scleroderma patients develop renal crisis at some point in the course of their disease.[14] Patients that have rapid skin involvement have the highest risk of renal complications.[14]

Treatments for scleroderma renal crisis include ACE inhibitors, which are also used for prophylaxis,[14][13] and renal transplantation. Transplanted kidneys are known to be affected by scleroderma and patients with early onset renal disease (within one year of the scleroderma diagnosis) are thought to have the highest risk for recurrence.[15]

Diagnosis

Diagnosis is by clinical suspicion, presence of autoantibodies (specifically anti-centromere and anti-scl70/anti-topoisomerase) and occasionally by biopsy. Of the antibodies, 90% have a detectable anti-nuclear antibody. Anti-centromere is more common in the limited form (80-90%) than in the systemic form (10%), and anti-scl70 is more common in the diffuse form (30-40%) and in African-American patients (who are more prone to the systemic form).[16]

In 1980 the American College of Rheumatology agreed upon diagnostic criteria for scleroderma.[17]

Types

There are three major forms of scleroderma: diffuse, limited (CREST syndrome) and morphea/linear. Diffuse and limited scleroderma are both a systemic disease, whereas the linear/morphea form is localized to the skin. (Some physicians consider CREST and limited scleroderma one and the same, others treat them as two separate forms of scleroderma.) There is also a subset of the systemic form known as "systemic scleroderma sine scleroderma", meaning the usual skin involvement is not present.

Diffuse scleroderma

Diffuse scleroderma is the most severe form - it has a rapid onset, involves more widespread skin hardening, will generally cause much internal organ damage (specifically the lungs and gastrointestinal tract), and is generally more life threatening.

Limited scleroderma/CREST syndrome

The limited form is much milder: it has a slow onset and progression, skin hardening is usually confined to the hands and face, internal organ involvement is less severe, and a much better prognosis is expected.

In typical cases of limited scleroderma, Raynaud's phenomenon may precede scleroderma by several years. Raynaud's phenomenon is due to vasoconstriction of the small arteries of exposed peripheries - particularly the hands and feet - in the cold. It is classically characterised by a triphasic colour change - first white, then blue and finally red on rewarming. The scleroderma may be limited to the fingers - known as sclerodactyly.

The limited form is often referred to as CREST syndrome. "CREST" is an acronym for:

Calcinosis

Raynaud's syndrome

Esophageal dysmotility

Sclerodactyly

Telangiectasia

These are the five major signs that make up the CREST syndrome.

Morphea/linear scleroderma

Morphea/linear scleroderma involves isolated patches of hardened skin - there generally is no internal organ involvement.[18]

Therapy

There is no cure for every patient with scleroderma, though there is treatment for some of the symptoms, including drugs that soften the skin and reduce inflammation. Some patients may benefit from exposure to heat.[citation needed]

A range of NSAIDs (nonsteroidal anti-inflammatory drugs) can be used to ease symptoms, such as naproxen. If there is esophageal dysmotility (in CREST or systemic sclerosis), care must be taken with NSAIDs as they are gastric irritants, and so a proton pump inhibitor (PPI) such as omeprazole can be given in conjunction.

Immunosuppressant drugs, such as mycophenolate mofetil (Cellcept®) or cyclophosphamide are sometimes used to slow the progress.

Digital ulcerations can be helped by prostacyclin (iloprost) infusion. Iloprost being a drug which increases blood flow by relaxing the arterial wall.

Causes

There is no clear obvious cause for scleroderma and systemic sclerosis. Genetic predisposition appears to be limited: genetic concordance is small; still, there often is a familial predisposition for autoimmune disease. Polymorphisms in COL1A and TGF-β1 may influence severity and development of the disease. There is limited evidence implicating cytomegalovirus (CMV) as the original epitope of the immune reaction, and organic solvents and other chemical agents have been linked with scleroderma.[16]

One of the suspected mechanisms behind the autoimmune phenomenon is the existence of microchimerism, i.e. fetal cells circulating in maternal blood, triggering an immune reaction to what is perceived as "foreign" material[19].[16]

Pathophysiology

The overproduction of collagen is thought to result from an autoimmune dysfunction, in which the immune system would start to attack the kinetochore of the chromosomes. This would lead to genetic malfunction of nearby genes. T cells accumulate in the skin; these are thought to secrete cytokines and other proteins that stimulate collagen deposition. Stimulation of the fibroblast, in particular, seems to be crucial to the disease process, and studies have converged on the potential factors that produce this effect.[16]

A significant player in the process is transforming growth factor (TGFβ). This protein appears to be overproduced, and the fibroblast (possibly in response to other stimuli) also overexpresses the receptor for this mediator. An intracellular pathway (consisting of SMAD2/SMAD3, SMAD4 and the inhibitor SMAD7) is responsible for the secondary messenger system that induces transcription of the proteins and enzymes responsible for collagen deposition. Sp1 is a transcription factor most closely studied in this context. Apart from TGFβ, connective tissue growth factor (CTGF) has a possible role.[16]

Damage to endothelium is an early abnormality in the development of scleroderma, and this too seems to be due to collagen accumulation by fibroblasts, although direct alterations by cytokines, platelet adhesion and a type II hypersensitivity reaction have similarly been implicated. Increased endothelin and decreased vasodilation has been documented.[16]

Jimenez & Derk[16] describe three theories about the development of scleroderma:

The abnormalities are primarily due to a physical agent, and all other changes are secondary or reactive to this direct insult.

The initial event is fetomaternal cell transfer causing microchimerism, with a second summative cause (e.g. environmental) leading to the actual development of the disease.

Physical causes lead to phenotypic alterations in susceptible cells (e.g. due to genetic makeup), which then effectuate DNA changes which alter the cell's behavior.

Epidemiology

Scleroderma affects approximately 300,000 people in the United States. It is four times as common in women than in men. Incidence rates are estimated at 2-20 per million per year in the United States.

Juvenile Scleroderma affects approximately 7000 children in the United States. Most common form of Juvenile Scleroderma is Localized Scleroderma - Morphea and/or Linear.

Patients' advocacy

The Juvenile Scleroderma Network is a volunteer-staffed 501(c)(3) non-profit organization dedicated to provide emotional support and educational information to parents and their children living with Juvenile Scleroderma; to support pediatric research to identify the cause of and the cure for Juvenile Scleroderma; to enhance the public's awareness of Juvenile Scleroderma.

The Scleroderma Foundation is a leading organization dedicated to raising awareness of the disease and assisting those who are affected. Its national spokesperson is Jason Alexander. Bob Saget is also very active in advocacy through the Scleroderma Research Foundation. Mr. Saget's sister died of the disease.

The Road Back Foundation, founded as a non-profit, charitable organization in 1993, is a peer-to-peer endeavor run entirely by volunteers -- professionals who are dedicated to providing information and support to people with rheumatic diseases.

References

^ a b c d Systemic sclerosis and related syndromes. Primer on the rheumatic diseases, 11th edition, The Arthritis Society, p. 269, 1997

^ Valentini G, Black C. Systemic sclerosis. Best Pract Res Clin Rheumatol. 2002 Dec;16(5):807-16. PMID 12473275

^ Olsen NJ, King LE Jr, Park JH. Muscle abnormalities in scleroderma. Rheum Dis Clin North Am. 1996 Nov;22(4):783-96. PMID. 8923596.

^ Steen VD. The lung in systemic sclerosis. J Clin Rheumatol 2005 Feb;11(1):40-6. PMID 16357695

^ a b c Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther. 2006 Mar 15;23(6):691-712. PMID 16556171

^ a b c Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am. 1998 Sep;27(3):563-94. PMID 9891698

^ Hendel L, Hage E, Hendel J, Stentoft P. Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther. 1992 Oct;6(5):565-77. PMID 1420748

^ Ruangjutipopan S, Kasitanon N, Louthrenoo W, Sukitawut W, Wichainun R. Causes of death and poor survival prognostic factors in thai patients with systemic sclerosis. J Med Assoc Thai. 2002 Nov;85(11):1204-9. PMID 12546318.

^ Steen VD, Mayes MD, Merkel PA. Assessment of kidney involvement. Clin Exp Rheumatol. 2003;21(3 Suppl 29):S29-31 PMID 12889219.

^ Steen VD. Renal involvement in systemic sclerosis. Clin Dermatol. 1994 Apr-Jun;12(2):253-8. PMID 8076263.

^ Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am. 2003 May;29(2):315-33. Review. PMID 12841297.

^ Rhew EY, Barr WG. Scleroderma renal crisis: new insights and developments. Curr Rheumatol Rep. 2004 Apr;6(2):129-36. Review. PMID 15016343.

^ a b Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000 Oct 17;133(8):600-3. PMID 11033587. [Free Full Text http://www.annals.org/cgi/reprint/133/8/600.pdf].

^ a b c Jimenez S, Koenig AS. Scleroderma. eMedicine.com. URL: http://www.emedicine.com/MED/topic2076.htm. Accessed: May 22, 2006.

^ Pham PT, Pham PC, Danovitch GM, Gritsch HA, Singer J, Wallace WD, Hayashi R, Wilkinson AH. Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant. 2005 Oct;5(10):2565-9. PMID 16162209.

^ a b c d e f g Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50. PMID 14706971.

^ http://www.rheumatology.org/publications/classification/systsclr.asp.

^ Morpea CNN.com, (May 05, 2006).

^ Bianchi DW. Fetomaternal cell trafficking: a new cause of disease? Am J Med Genet 2000;91:22-8. PMID 10751084.

Info & Disclaimer: The Diseases category of the BillDoll Health Reference provides reference and resources for specific diseases and illnesses in the context of symptoms, diagnosis, treatments, and cures. It also provides inputs on doctors, hospitals and medicines, drugs in some cases. Please note that all these inputs are provided for information purposes only. You are advised to get qualified medical opinion before embarking / acting on any treatment, cure, doctor, medicine, drug or hospital.

Main Sections @ The Billion Dollar Site

Credits & Copyright: This page is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article Scleroderma

Reference

GeoDig – Get Local!

Have you checked out the GeoDig directories for over 30 countries? GeoDig provides useful local and regional web resources for over 200 cities around the world. See the list of cities and countries for which GeoDig provides locality-specific web resources.

North America

USA - Alabama (AL) > Birmingham; Alaska; Arkansas (AR) > Little Rock; Arizona (AZ) > Phoenix, Las Vegas, Tucson; California (CA) > Los Angeles, San Francisco, Sacramento, Fresno, Bakersfield; Colorado, CO > Denver; Connecticut, CT > Hartford; District of Columbia, DC > Washington DC; Delaware (DE) > Wilmington; Florida > Miami, Orlando, Tampa, Orlando, Sarasota, West Palm Beach, Jacksonville; Georgia > Atlanta; Hawaii > Honolulu; Idaho; Illinois > Chicago; Indiana > Indianapolis; Iowa; Kansas (KS); Kentucky (KY) > Louisville; Louisiana (LA) > New Orleans, Baton Rouge; Maine; Maryland (MD) > Baltimore; Massachusetts > Boston, Springfield; Michigan > Detroit, Grand Rapids; Minnesota > Minneapolis-St. Paul; Mississippi (MS); Missouri (MO) > Kansas City, St. Louis; Montana; Nebraska (NE) > Omaha; Nevada (NV) > Las Vegas; New Hampshire; New Jersey (NJ) > Jersey City, Newark; New Mexico (NM) > Albuquerque; New York > New York, Buffalo, Rochester, Albany, Syracuse; North Carolina (NC) > Raleigh-Durham, Charlotte, Greensboro; North Dakota; Ohio> Columbus, Cincinnati, Cleveland, Toledo, Youngstown, Dayton; Oklahoma (OK) > Oklahoma City, Tulsa; Oregon > Portland; Pennsylvania > Philadelphia, Allentown, Pittsburgh, Harrisburg, Scranton, ; Rhode Island (RI) > Providence; South Carolina (SC) > Greenville; South Dakota; Tennessee (TN) > Knoxville, Memphis, Nashville; Texas > Austin, Dallas, Houston, San Antonio, El Paso, Austin, McAllen; Utah (UT) > Salt Lake City; Vermont; Virginia (VA) > Norfolk, Richmond; Washington > Seattle; West Virginia; Wisconsin (WI) > Milwaukee; Wyoming

Canada - Vancouver, Montreal, Toronto, Calgary, Ottawa-Gatineau, Edmonton, Quebec City, Winnipeg, Hamilton, London

You are the Scleroderma page @ the Health Section of BillDoll Reference

Europe - UK - London, Glasgow, Manchester, Birmingham, Liverpool, Sheffield, Leeds, Bristol, Edinburgh, Leicester; France - Paris, Marseille, Lyon, Toulouse, Nice, Nantes, Strasbourg, Montpellier, Bordeaux; Germany - Frankfurt (Frankfurt am Main), Munich (München), Berlin, Düsseldorf, Hamburg, Cologne (Köln), Essen, Dortmund, Stuttgart, Bremen, Duisburg, Hannover, Nürnberg (Nuremberg), Dresden, Leipzig; Italy - Milan (Milano), Rome (Roma), Napoli (Naples), Torino (Turin), Palermo, Bologna, Firenze (Florence), Genova (Genoa); Spain - Madrid, Barcelona, Valencia, Sevilla, Zaragoza, Malaga, Murcia, Las Palmas, Bilbao; Scandinavia - Finland - Helsinki (Helsingin), Espoo, Tampere (Tampereen), Vantaa, Turku, Oulu, Sweden - Stockholm, Goteborg (Göteborg), Malmo (Malmö), Uppsala, Vasteras (Västerås), Denmark - Copenhagen (Københavns), Aarhus (Århus), Odense, Aalborg (Ålborg), Norway - Oslo, Bergen, Stavanger, Trondheim; Benelux - Belgium - Brussels (Brussel), Antwerp (Antwerpen), Ghent (Gent, Gand), Charleroi, Liège (Liege), Netherlands - Amsterdam, Rotterdam, Utrecht, Eindhoven, Tilburg, ‘s-Gravenhage (sGravenhage), Groningen, Luxembourg - Luxembourg City; Portugal – Lisbon; Greece – Athens; Hungary – Budapest; Poland – Warsaw; Switzerland - Zürich (Zurich), Geneva (Geneve, Genève), Basel, Bern (Berne), Lausanne; Austria - Linz, Vienna (Wien), Graz, Linz, Salzburg, Innsbruck; Ireland – Dublin

Asia - India - Mumbai, New Delhi, Bangalore; China & Hong Kong - Hong Kong, Beijing, Shanghai, Tianjin, Wuhan, Shenyang, Guangzhou, Harbin, Xian; Japan - Tokyo, Osaka, Yokohama, Nagoya, Sapporo, Kyoto, Kobe, Fukuoka, Kawasaki, Hiroshima; South Korea - Seoul, Pusa, Taegu, Incheon, Taejeon, Taiwan - Taipei; Malaysia - Kuala Lumpur; Singapore; Russia - Moscow, St Petersburg

You are the Scleroderma page @ the Health Section of BillDoll Reference

Middle East - Turkey - Istanbul, Israel - Tel Aviv

Oceania - Australia - Sydney, Melbourne, Brisbane, Perth, Adelaide

Africa - South Africa - Johannesburg, Cape Town, Durban

BillDoll.com – The Billion Dollar Site